Yesterday, one of the more interesting development-stage drugmakers, Alexza Pharmaceuticals
Alexza ended the second quarter with $134 million in cash and investments, counting the cash held in an account with Symphony Allegro. The company used $11 million cash in the quarter so its current financial position is secure. Current estimates are for its cash and investments on hand to last until the middle of 2009.
Alexza has estimated that its technology could work with nearly 200 already marketed drugs. While only a portion of these compounds will likely be commercially viable, this gives it a large stable of compounds to choose from when developing aerosolized versions of different drugs.
Yesterday, Alexza also announced that it had initiated meetings with the FDA to start clinical trials for a new pipeline drug candidate. The compound is an inhalable version of King Pharmaceuticals'
There's always a balance to strike between strengthening a drug development pipeline and conserving dwindling cash balances. To deal with its cash burn rate and investor concerns about the market potential for its drug candidates, Alexza needs to ink a healthy development deal for its lead drugs with a strong marketing partner like Cephalon
Looking for more Foolish drug stock coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can see all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
More from The Motley Fool
People's United Financial, Inc. (PBCT) Q4 2017 Earnings Conference Call Transcript
PBCT earnings call for the period ending December 31, 2017.
IBM Struggled With the Tax Man in the 4th Quarter
A long-awaited return to actual sales growth was overshadowed by a $5.5 billion one-time tax charge.
1 Big Improvement That Apple Needs to Bring to the New iPhone SE
It's time for a new display.